November 18, 2026
Health news, explained with evidence
LIVE

Researchers Identify Mechanism Driving Triple-Negative Breast Cancer Growth

🔬 Research 2 min read 👁 8

A study reveals that microRNA from neighboring cells helps triple-negative breast cancer proliferate, suggesting a potential new target for existing therapies.

Researchers Identify Mechanism Driving Triple-Negative Breast Cancer Growth🔬Research

Photo: Medical Xpress

Key points

  • Triple-negative breast cancer is an aggressive form of cancer with limited targeted treatment options.
  • Fibroblast-derived miR-1290 promotes tumor growth by suppressing a key tumor-inhibiting protein.
  • The study suggests that the drug everolimus may help block this growth mechanism.
  • Blood levels of miR-1290 could potentially serve as a diagnostic biomarker for patient outcomes.

Researchers at the Korea Research Institute of Bioscience and Biotechnology and Kyungpook National University have discovered that a specific microRNA, known as miR-1290, plays a critical role in the progression of triple-negative breast cancer. This subtype of cancer, which accounts for approximately 15% of all breast cancer cases, is known for its aggressive nature and limited treatment options, often requiring chemotherapy due to a lack of targeted therapy alternatives.

The study, published in Signal Transduction and Targeted Therapy, explains that cancer-associated fibroblasts—cells that typically provide structural support—release exosomes containing miR-1290. Once these exosomes enter cancer cells, they reduce the levels of a tumor-suppressing protein called TBC1D4. This process triggers growth signals that accelerate the proliferation of the tumor.

In laboratory and animal models, the research team demonstrated that the drug everolimus, which is already approved for other cancer types, could effectively block this growth-promoting pathway. Furthermore, the researchers observed that elevated levels of miR-1290 in the blood of patients correlated with more rapid cancer progression, indicating its potential as a future diagnostic or prognostic biomarker.

What to know: While these findings offer a promising new pathway for treatment, they are based on early-stage laboratory and animal models. Patients should consult with their oncologists regarding current standard-of-care treatments and clinical trial opportunities.

Source Medical Xpress — medicalxpress.com/news/2026-11-small-rna-cells-triple-negative.html ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.